Management of non-small cell lung cancer with EGFR mutation: the role of radiotherapy in the era of tyrosine kinase inhibitor therapy—opportunities and challenges

Similar Items

• Combined action of EGFR tyrosine kinase inhibitors and whole-brain radiotherapy on EGFR-mutated non-small-cell lung cancer patients with brain metastasis
  od: Lu, Yunyun, i dr.
  Izdano: (2016)
• Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with EGFR Mutations
  od: Suda, Kenichi, i dr.
  Izdano: (2021)
• Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations
  od: Wang, Jun, i dr.
  Izdano: (2016)
• EGFR Mutation Heterogeneity and the Mixed Response to EGFR Tyrosine Kinase Inhibitors of Lung Adenocarcinomas
  od: Chen, Zhi-Yong, i dr.
  Izdano: (2012)
• Management of tyrosine kinase inhibitor resistance in lung cancer with EGFR mutation
  od: Becker, Kevin, i dr.
  Izdano: (2014)